Over the last year, Wafergen has been pumping plenty of cash into R&D and working with several early-access partners to further develop and test its SmartChip real-time PCR system in anticipation of a commercial launch later this year.

But the company faces the prospect that it will run out of cash before it can launch its flagship product, according to a prospectus filed this month with the Securities and Exchange Commission.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.